A inflammatory syndrome in adults infected by the SARS-CoV-2 with severe illness requiring hospitalization in a person aged ≥21 years; a positive test result for current or previous SARS-CoV-2 infecti...
Comprehensive, easy-to-understand information about this condition
How we create this content →Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 5, 2026
Common questions about COVID-19–associated multisystem inflammatory syndrome in adults
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 1 company has orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning COVID-19–associated multisystem inflammatory syndrome in adults
Updated Feb 4, 2026
Nearly 100 biotech companies went public in 2021, driven by pandemic investments, but many struggle to deliver results. Invivyd raised $336 million in a Series C round for its COVID-19 candidate ADG20, while Verve focuses on gene editing for cardiovascular diseases.
The CDC reports on the effectiveness of COVID-19 vaccines in children aged 9 months to 17 years, providing critical data for public health policy. This analysis covers the period from August 29, 2024, to September 2, 2025.
The CDC has launched a Nursing Home Data Dashboard featuring a COVID-19 module that tracks the impact on residents and staff in long-term care facilities. This initiative aims to enhance transparency and inform policy decisions regarding nursing home safety.
The FDA has issued Emergency Use Authorizations (EUA) for certain medical devices related to COVID-19, as mandated by the Federal Food, Drug, and Cosmetic Act. This announcement includes the requirement for the FDA to publish notices of each authorization in the Federal Register.
FDA revokes Emergency Use Authorizations for the Lucira by Pfizer COVID-19 & Flu Test and the Lucira by Pfizer COVID-19 & Flu Home Test at the request of Pfizer Inc. The decision reflects ongoing evaluations of diagnostic device efficacy and safety.